Clinical outcomes between different stent designs with the same polymer and drug: comparison between the Taxus Express and Taxus Liberte stents.
10.3904/kjim.2013.28.1.72
- Author:
Jang Won SON
1
;
Ung KIM
;
Jong Seon PARK
;
Young Jo KIM
;
Jae Sik JANG
;
Tae Hyun YANG
;
Dong Soo KIM
;
Dong Kie KIM
;
Sang Hoon SEOL
;
Doo Il KIM
;
Chang Wook NAM
;
Seung Ho HUR
;
Kwon Bae KIM
Author Information
1. Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
- Publication Type:Original Article ; Comparative Study ; Multicenter Study
- Keywords:
Angioplasty;
Drug-eluting stents;
Polymers
- MeSH:
Aged;
Angioplasty, Balloon, Coronary/adverse effects/*instrumentation/mortality;
Cardiovascular Agents/administration & dosage;
Chi-Square Distribution;
Coronary Angiography;
Coronary Artery Disease/mortality/radiography/*therapy;
Coronary Restenosis/etiology/mortality;
Coronary Thrombosis/etiology/mortality;
*Drug-Eluting Stents;
Female;
Humans;
Male;
Middle Aged;
Myocardial Infarction/etiology/mortality;
Paclitaxel/*administration & dosage;
Propensity Score;
Prosthesis Design;
Registries;
Republic of Korea;
Retrospective Studies;
Risk Factors;
Stainless Steel;
Time Factors;
Treatment Outcome
- From:The Korean Journal of Internal Medicine
2013;28(1):72-80
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: The Taxus Liberte stent (Boston Scientific Co.) evolved from the Taxus Express stent, with enhanced stent deliverability and uniform drug delivery. This study was designed to compare angiographic and clinical outcomes in real-world practice between the Taxus Liberte and Taxus Express stents. METHODS: Between 2006 and 2008, 240 patients receiving the Taxus Liberte stent at three centers were registered and compared to historical control patients who had received the Taxus Express stent (n = 272). After propensity score matching, 173 patients treated with the Taxus Liberte stent and the same number of patients treated with the Taxus Express stent were selected. The primary outcome was a composite of major adverse cardiac events (MACE), including cardiac death, myocardial infarction (MI), ischemia driven target vessel revascularization (TVR), and stent thrombosis (ST) at 1 year. An additional angiographic assessment was conducted at 9 to 12 months. RESULTS: The study showed no significant difference between the Taxus Express and Taxus Liberte stents (death, 1.73% vs. 2.31%, p = 1.000; MI, 0% vs. 1.73%, p = 0.2478; TVR, 2.31% vs. 1.16%, p = 0.6848; and ST, 0% vs. 1.16%, p = 0.4986). The total MACE rate at 1 year did not differ between the groups (4.05% in Taxus Express vs. 4.05% in Taxus Liberte, p = 1.000). In addition, the binary restenosis rate did not differ (2.25% in Taxus Express vs. 1.80% in Taxus Liberte, p = 0.6848). CONCLUSIONS: In real-world experience with the two Taxus stent designs, both stents showed similarly good clinical and angiographic outcomes at 1 year. A long-term follow-up study is warranted.
